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Malnutrition is one of the most common complications of cirrhosis, associated with an increased risk of morbidity and
mortality. As a potentially modifiable condition, it is of particular importance to identify malnourished patients so that
nutritional therapy can be instituted. Nutrition screening and assessment are infrequently performed in patients with cir-
rhosis. The reasons for this are multifactorial, including the absence of a validated “rapid” screening tool, multiple defini-
tions of what constitutes malnutrition, and challenges with interpreting body composition and laboratory results in the
setting of volume overload and liver dysfunction. This article summarizes the clinically relevant evidence and presents key
issues, tools, and clinical options that are applicable to patients with cirrhosis. The definition, etiology, and clinically rele-
vant outcomes associated with malnutrition are reviewed. Rapid nutritional screening is differentiated from more detailed
nutritional assessment. Nutritional assessment in special populations, including women and the obese, and the role of
inflammation are discussed. Multicenter studies using a common nutritional screening/assessment strategy are the
next steps to fast-track adoption and implementation of nutrition-related evaluations into routine clinical practice.
(HEPATOLOGY 2017;65:1044-1057).
Malnutrition is one of the most commoncomplications associated with cirrhosis andis diagnosed in anywhere from 5% to 99%
of patients depending upon the assessment methods
that are used.(1) Malnutrition is associated with
increased risk of mortality, higher prevalence of portal
hypertension–related complications and infections, as
well as longer stays in hospital.(2-4) In mixed popula-
tions of malnourished patients, the benefits of nutri-
tion therapy are evidenced by reductions in mortality,
infections, systemic inflammatory responses, and hos-
pital length of stay.(5,6) Although cirrhosis-specific
studies are limited by cohort size and trial design,
nutrition therapy has also shown benefit.(7)
As a potentially modifiable condition, it is of partic-
ular relevance to identify malnourished patients so that
nutritional therapy can be instituted. Ideally, all
patients should first undergo a rapid nutrition screen
to determine if they are at risk of malnutrition. Those
at risk should complete a more detailed nutritional
assessment to confirm the presence and severity of
malnutrition.(8) Nutrition screening and assessment
are performed infrequently in patients with cirrhosis
due to the absence of a validated “rapid” screening tool,
multiple definitions of what constitutes malnutrition,
and challenges with interpreting body composition and
laboratory results in the setting of volume overload and
liver dysfunction.
This article presents key issues, tools, and clinical
options to enhance the practice of nutrition screening
and assessment that are applicable to both outpatients
and hospitalized patients with cirrhosis. A PubMed
search using the search terms “malnutrition,”
“nutritional assessment,” “cirrhosis,” and related terms
was carried out in April 2016 and supplemented by
articles identified from the gray literature and the
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authors’ content expertise. Due to the limited evidence
in this area, this article also incorporates the authors’
opinions and experience to raise awareness and provide
a practical approach applicable to the clinical setting.
The details of the nutrition prescription, including
methods of calculation and nutrient distribution, and
the approach to nutritional therapy in patients with
cirrhosis are also important topics but fall beyond the
scope of the current review.
Defining Malnutrition in
the Setting of Cirrhosis
“Malnutrition” can refer to a state of either undernu-
trition or overnutrition. For the purpose of this review,
“malnutrition” will be used synonymously with
“undernutrition.” Malnutrition is diagnosed following
a comprehensive nutritional assessment. Major nutri-
tion and cirrhosis research groups/organizations have
proposed expert consensus-based definitions of malnu-
trition, including the American Society for Parenteral
and Enteral Nutrition (ASPEN),(9) the European
Society for Parenteral and Enteral Nutrition
(ESPEN),(10,11) the International Society for Hepatic
Encephalopathy and Nitrogen Metabolism,(1) and a
recent guideline in the American Journal of Gastroenter-
ology.(6) Some of these guidelines are targeted to a gen-
eral cohort of adult patients, and others are specific to
cirrhosis. Although there is no unifying tool for the
diagnosis of malnutrition, there is significant overlap in
the components used to objectively define malnutri-
tion, with all societies notably recommending some
form of muscle mass assessment (Table 1).
It is accepted that malnutrition increases with wors-
ening liver disease severity. To date, however, in the
cirrhosis-specific guidelines, liver disease severity has
not been used to stratify patients for their risk of mal-
nutrition. In addition to the well-accepted body mass
index (BMI) of <18.5 kg/m2(10) to define malnutri-
tion, we propose that Child-Pugh C patients are at
very high risk of malnutrition and do not need to be
“screened” for malnutrition but instead can proceed
directly to a nutritional assessment (Fig. 1).
Towards a Practical Approach:
 There is a compelling need for consensus
on accurate and readily useable tools to
diagnose malnutrition in cirrhosis.
 Cirrhosis patients with a BMI <18.5 or
those with Child-Pugh C are at high risk
for malnutrition.
Etiology and Mechanisms of
Malnutrition in Hepatic
Cirrhosis
The etiology of malnutrition in cirrhosis involves
multiple processes resulting from combined disturban-
ces of oral intake, absorption, and metabolism of
nutrients.(12) First, impaired dietary intake is a princi-
pal cause of malnutrition and may arise as a conse-
quence of gastrointestinal symptoms, anorexia,
dysgeusia, and prescription of unpalatable diets.
Anorexia may be triggered by an imbalance between
orexigenic and anorexigenic hormones and by the
chronic increase in circulating cytokines. Nausea, vom-
iting, and early satiety are often related to intra-
abdominal pressure secondary to ascites. Dysgeusia
may result from zinc deficiency, while unpalatability is
often the result of rigid sodium-restricted diets.
Second, nutrient malabsorption may occur in
patients with cirrhosis due to multiple factors, the
mechanisms for which are incompletely understood.(13)
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Fat malabsorption, secondary to decreased production
of bile acids, occurs in cholestatic liver diseases. Intra-
luminal bile acid deficiency, resulting from decreased
bile production and portosystemic shunting, impairs
micelle formation and absorption of long chain fatty
acids through lymphatics. Pancreatic insufficiency fre-
quently coexists in patients with alcoholic cirrhosis.
Portal hypertensive gastropathy and enteropathy,
altered intestinal flora, and chronic lactulose use may
also lead to malabsorption.
Third, altered macronutrient metabolism is a cor-
nerstone mechanism contributing to malnutrition in
cirrhosis. Carbohydrate metabolism is abnormal (e.g.,
peripheral insulin resistance, hyperinsulinemia,
impaired hepatic glycogen synthesis) and promotes
gluconeogenesis from amino acids, glycerol, pyruvate,
and lactate. These effects are already evident after a
short overnight fast and may resemble the catabolic
state of healthy subjects undergoing 2-3 days of star-
vation. Abnormal amino acid metabolism leads to low
plasma levels of methionine and branched chain ami-
no acids, which associate with muscle atrophy. Pro-
tein catabolism is increased in the postabsorptive
state, and protein synthesis that usually occurs in
response to a meal is normal or attenuated compared
with matched controls. Hypermetabolism is a rela-
tively infrequent feature in stable cirrhosis and is not
associated with sex, etiology, or severity of liver dis-
ease; however, it may result from up-regulation of the
sympathetic nervous system, and hypermetabolism
has been reported when energy expenditure is
expressed per kilogram of lean body mass. Recent
research has also increased our knowledge about
molecular mechanisms contributing to the pathophys-
iology of muscle wasting in patients with cirrhosis,
and more information can be derived from a recent
review on this topic.(14)
Towards a Practical Approach:
 Malnutrition in cirrhosis is multifactorial.
 Treating malnutrition requires a compre-
hensive and multidisciplinary strategy and
surveillance.
Relationship of Malnutrition
and Clinical Outcomes in
Cirrhosis
Historically, malnutrition was believed to influence
the health outcome of patients with liver cirrhosis. As
such, it was included in the 1964 Child-Turcotte classi-
fication for the prognosis of patients with cirrhosis
undergoing surgery. In 1972, the nutritional status
parameter was removed. Since then, many studies on
cirrhosis have associated malnutrition with worse health
outcomes and lower survival rates (Fig. 2).(2-4,15,16)
Multiple methods have been applied to evaluate
malnutrition (e.g., Subjective Global Assessment
[SGA], anthropometry, nutritional index, dual X-ray
absorptiometry, computed tomography [CT]/magnetic
resonance imaging [MRI]), which has led to divergent
results. The depletion of muscle mass (commonly
termed “sarcopenia”) has emerged as the “central core”
of the nutrition assessment in cirrhosis. Muscle tissue
stores a large proportion of amino acids and proteins,
which are mobilized in catabolic conditions. Muscle is
crucial for mobility, metabolic regulation of glucose
and lipids, heart and respiratory function, immune
function, and cytokine activity. Muscle wasting, quan-
tified either by anthropometry or by imaging techni-
ques, is related to a higher rate of mortality in patients
with cirrhosis.(3,4,15,16) The strong interplay between
malnutrition, sarcopenia, and poor prognosis is further
demonstrated by the association of nutritional impair-
ment and liver disease–related complications.(17,18)
TABLE 1. Society Guidelines for Defining Malnutrition—Common Components
Food
intake
Weight
loss
Muscle
mass loss
Subcutaneous
fat loss
Fluid
accumulation
Functional
status BMI Inflammation SGA
General ASPEN(1) X X X X X X X
Hospitalized inpatient(2) X X
General ESPEN(3) X X X
Cirrhosis ESPEN(4) X X X X X
Cirrhosis ISHEN(5) X X X X X X
Abbreviation: ISHEN, International Society for Hepatic Encephalopathy and Nitrogen Metabolism.
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In patients with hepatocellular carcinoma, sarcopenia
is an independent prognostic factor decreasing surviv-
al(19) and increasing treatment complications and related
mortality.(20) Sarcopenia plays a negative prognostic role
in candidates for surgical treatment of hepatocellular
carcinoma. Malnutrition is also a well-established risk
factor in patients with cirrhosis undergoing surgery.
In patients awaiting liver transplantation, muscle
depletion is predictive of increased waiting list
mortality as the majority of these are patients with
decompensated cirrhosis and advanced liver insuffi-
ciency.(4) Following transplantation, malnourished
patients commonly present with increased length of
hospitalization, prolonged intensive care unit stay, lon-
ger time of intubation, and higher rate of infections
compared with those who are well nourished.(21)
Although it is generally accepted that malnourished
patients may require greater support in the posttrans-
plantation setting,(22) malnutrition is not currently
considered a contraindication to transplantation.
Towards a Practical Approach:
 Evidence suggests that malnutrition is an
independent predictor of poor clinical out-
comes and lower survival in cirrhosis.
 Loss of muscle mass loss is objectively
measureable and has been the most com-
mon nutritional variable associated with
mortality.
Nutrition Screening and
Nutrition Risk
ASPEN defines nutrition screening as a process to
identify individuals who are malnourished or at risk of
malnutrition for referral to a comprehensive nutritional
assessment and intervention if appropriate.(23) ESPEN
states that screening should be a rapid and simple pro-
cess conducted by admitting staff or community health
care teams.(24) An ideal screening tool should be usable
by an untrained health care professional (or even the
patient) and have reasonable sensitivity and specific-
ity.(25) Routine system-wide nutrition screening is not
widely practiced, even though it is recommended for
high-risk patient groups. As such, patients at risk for
malnutrition are often overlooked until they are mal-
nourished and/or have a major health event requiring
intervention. By ignoring preventative strategies, mal-
nutrition increases the economic burden of cirrhosis.(26)
Nutrition risk acknowledges the interplay between
inflammation and malnutrition and is determined by
not only nutritional status but also disease severi-
ty.(6,27,28) ESPEN defines nutrition risk as “Chances of
a better or worse outcome from disease or surgery
according to actual or potential nutritional and metabol-
ic status.”(8) The literature does not provide a
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FIG. 1. A proposed algorithm for nutritional screening and
assessment in patients with cirrhosis.
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FIG. 2. Overview of the complex relationship between malnutri-
tion, cirrhosis-related complications, transplantation, and survival.
Data about the prognostic value of malnutrition for survival after
liver transplantation are controversial.
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unanimous definition for nutrition screening, and there
is no consensus regarding the concept of nutrition
risk.(8)
Nutritional Risk Screening 2002(28) and the Nutrition
Risk in Critically Ill(27) are examples of two scoring sys-
tems to determine nutrition risk. Other validated nutri-
tion screening tools can be used as general screens for
malnutrition (Table 2).(29) Althoughmany tools demon-
strate sensitivity and specificity values over 70% (mini-
mally accepted prerequisite), flaws in the validation
processes have been observed,(25) including the use of
expert trained professionals and lack of validation of tool
administration by nonexperts (e.g., nutrition assistants,
diet technicians, or nurses). Importantly, to date, none of
the frequently recognized nutrition screening tools
(Table 2) have been validated in the setting of cirrhosis.
Which Nutrition Screening/
Nutrition Risk Tool(s) Can
Be Used in Cirrhosis?
Cirrhosis-specific tools have been developed. The
Royal Free Hospital-Nutritional Prioritizing Tool
(RFH-NPT) was developed by validation against the
TABLE 2. Summary of Nutrition Screening Tools
Screening Tool
 Care Setting Advantages Disadvantages Tool Components
MUST(6)
 Community
High interrater reliability
Content and predictive validity for length
of hospital stay and mortality
Practical
Weight from fluid collections (ascites,
peripheral edema) not accounted
Disease severity not considered
BMI
Unplanned weight loss
in past 3-6 months
Acutely ill and unable to
eat for 5 days
NRS-2002(7)
 Hospital
Content and predictive validity
Moderately reliable
Practical
Considers disease severity
Weight from fluid collections (ascites,
peripheral edema) not accounted
Weight loss
Food intake
BMI
Disease severity
NUTRIC(2)
 Critically ill
Externally validated (n 5 >1,000
patients)
Interleukin-6 not widely available
Requires training
Classic nutrition parameters not
considered
Age
APACHE II and SOFA scores
Comorbidities
Days in hospital pre-ICU
Interleukin-6
MNA(8)
 Elderly (home-care
programs, nursing
homes, and hospitals)
Includes physical and mental
components plus dietary questionnaire
Predictive validity for adverse
outcome, social functioning, mortality,
and doctor visits
Practical
Content validity not reported
Interrater reliability modest
Weight from fluid collections (ascites,
peripheral edema) not accounted
Disease severity not considered
GI symptoms
Weight loss
Mobility
Psychological stress/acute
disease
Neuropsychological problems
BMI
SNAQ(9)
 Hospital
Simple/practical
Facilitates identification and treatment of
malnourished inpatients
Weight from fluid collections (ascites,
peripheral edema) not accounted
Disease severity not considered
Unintentional weight loss
Decreased appetite
Use of supplements or tube feeding
MST(10)
 Hospital
Simple/practical
Predictive validity for length of stay
Excellent reliability
Highly sensitive
Weight from fluid collections (ascites,
peripheral edema) not accounted
Disease severity not considered
Unintentional weight loss
Quantity of weight lost
Decreased appetite
RFH-NPT(11)
 Ambulatory
Hospital
Simple/practicalcirrhosis-specific features
Excellent intraobserver and interobserver
reproducibility
Good external validity
Predictive of clinical deterioration and
transplant-free survival
Valid in population with cirrhosis only
Impact of nutritional therapy based on
screening score unknown
Alcoholic hepatitis or tube feeding
Considers fluid overload
Dietary intake reduction
Weight loss 1 option for assessing
diuretic use
CNST(12)
 Hospital
Simple/practical
Validated against SGA (sensitivity 67%-
73%, specificity 80%-86%)
High reliability
Weight from fluid collections (ascites,
peripheral edema) not accounted
Disease severity not considered
Symptoms not considered
Unintentional weight loss
Dietary reduction
Abbreviations: APACHE II, Acute Physiology and Chronic Health Evaluation II; CNST, Canadian Nutrition Screening Tool; GI,
gastrointestinal; MNA, Mini Nutritional Assessment; MST, Malnutrition Screening Tool; MUST, Malnutrition Universal Screening
Tool; NRS-2002, Nutritional Risk Screening 2002; NUTRIC, Nutrition Risk in Critically Ill; SNAQ, Short Nutritional Assessment
Questionnaire; SOFA, Sequential Organ Failure Assessment.
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Royal Free Hospital SGA (Supporting Fig. S1).(1) It
takes 3 minutes to complete; discriminates patients
into low, medium, and high-risk categories; and
includes the variables of alcoholic hepatitis, fluid over-
load and impact on dietary intake, BMI, unplanned
weight loss, and reduced dietary intake (Supporting
Fig. S2). Importantly, the Malnutrition Universal
Screening Tool (recommended by ESPEN as the pre-
ferred screening tool for outpatients) is incorporated
within the RFH-NPT in patients who do not have flu-
id overload. In a series of 148 patients, the RFH-NPT
was identified as an independent predictor of clinical
deterioration and transplant-free survival.(30) The con-
tent validity of this tool in a population with cirrhosis
is promising and encompasses features of clinical and
metabolic risk, along with classical nutritional variables
that may influence response to nutrition therapy.
Additionally, although it includes BMI as a variable,
this is only considered in the absence of fluid overload.
A second liver-specific nutrition screening tool is the
Liver Disease Undernutrition Screening Tool (Support-
ing Fig. S3). This tool uses a series of six patient-
directed questions covering the domains of nutrient
intake, weight loss, subcutaneous fat loss, muscle mass
loss, fluid accumulation, and decline in functional status
to determine whether undernutrition is present or
absent. This tool was based on the Academy of Nutri-
tion and Dietetics and ASPEN consensus statements
for identifying malnutrition(31) and may have limitations
as it relies on the patient’s subjective judgment of each
of the measured parameters. Preliminary data compar-
ing it against a dietitian’s nutrition assessment in a
setting of cirrhosis (n 5 22) suggest that the Undernu-
trition Screening Tool had a high positive predictive
value (93%) but a low negative predictive value (37.5%),
leading to the conclusion that a negative screen was
unable to reliably rule out undernutrition. As with the
RFA-NPT, further validation is needed with compari-
son to clinical outcomes in patients with cirrhosis.
Towards a Practical Approach:
 Screening tools including either weight or
BMI have limited clinical value in cirrhosis
due to known fluctuations in body water.
 The cirrhosis-specific nutrition risk screen-
ing tool, RFH-NPT, is currently preferred
as it considers metabolic and nutritional
parameters.
Overview of the
Components of a Detailed
Nutritional Assessment
Once patients with cirrhosis have been screened, a
detailed nutrition assessment should be performed in
patients at high nutritional risk to confirm the nutri-
tion risk assessment, characterize nutrition status, and
identify modifiable variables for nutrition support.
Repeated assessments can monitor the effects of nutri-
tion therapy. As nutritional assessment is more com-
prehensive, is time-consuming, and requires
interpretation of multiple nutrition indicators, it is
preferable but not mandatory to have this performed
by a registered dietitian or a dedicated person with spe-
cialized knowledge.
In patients with cirrhosis whose screen results indi-
cate a high risk for malnutrition, we suggest that each
component be assessed and documented every 1-6
months in outpatients as well as inpatients at admis-
sion and periodically throughout their hospital stay.
Regardless of which tools are used, clinically relevant
information is obtained and awareness of nutrition
risks is raised by repeating the assessments in patients
with cirrhosis to improve quality of health care.
Although the assessment provided below focuses on
macronutrient deficiencies, patients with advanced liv-
er disease are also at risk of micronutrient deficiencies.
Zinc deficiency may be observed as a consequence of
diuretic use and restricting animal protein intake.
Hypomagnesemia may arise secondary to diuretic use.
Frequently, fat-soluble vitamin deficiencies, particular-
ly of vitamins A and D, are encountered. Considering
the high prevalence of micronutrient deficiencies in
this population, it is reasonable to incorporate basic
micronutrient screening into the broader nutrition
assessment. There are few guidelines to reference
regarding the frequency of micronutrient screening.
At a minimum, our group would recommend 6-
monthly testing of serum magnesium, serum 25-
hydroxyvitamin D3 and vitamin A, and serum zinc
levels.
#1 DIETARY ASSESSMENT
Dietary Intake
A detailed assessment of dietary intake (i.e., food,
fluids, and supplements) may include a 3-day food dia-
ry. Notably, this method is only useful if patients are
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provided with standardized instructions to understand
how to complete the diary properly. Although this for-
mal assessment may be burdensome for the patient,
the diary is preferred over a 24-hour dietary recall,
which is simple to use but heavily reliant on recall skills
and may not accurately represent routine food choices
and behaviors.
With the exception of dietitians, most health care
providers have insufficient “food” knowledge to incor-
porate, analyze, and interpret these tools during rou-
tine clinical practice. At a minimum, patients should
be asked if their relative food intake has changed and,
if so, over what duration. Although it requires valida-
tion in cirrhosis, parts of the abridged scored Patient-
Generated SGA, developed and validated in oncologi-
cal patients (Supporting Fig. S4),(32) may be useful to
initiate nutritional intake discussions with patients
who have cirrhosis. Given the detrimental effects of
fasting in cirrhosis, additional questions should be
asked, such as the duration of fasting between meals,
snacking routines, and use of nutritional supplements.
Inadequate protein intake is linked to sarcopenia and
has also been independently associated with mortality
in patients with cirrhosis(33); therefore, inquiry into
adequate protein sources is important.
Barriers to Dietary Intake
To effectively address oral intake, it is also essential to
delve into the factors that may compromise intake (e.g.,
dysgeusia, taste fatigue, low-sodium diet, early satiety,
socioeconomic factors). Tools such as the abridged
scored Patient-Generated SGA(32) can be useful. Valida-
tion of such tools is required in cirrhosis, but engaging
dietetic staff is helpful in assessing this information.
#2 BODY COMPOSITION
ASSESSMENT WITH A FOCUS ON
MUSCLE MASS
Body composition is an important parameter for
evaluation in nutrition assessment; however, choosing
a modality can be challenging, and one needs to con-
sider feasibility, cost, and level of accuracy or precision
that is required in practice. Body size by weight or
BMI provides a crude classification of patients in the
underweight, normal weight, overweight, or diverse
obese categories. There is no well-validated means of
adjusting BMI for the fluid retention that occurs in
cirrhosis. Similarly, bioelectrical impedance analysis
(BIA) offers the opportunity for quick and easy
determinations of lean mass; however, BIA is highly
influenced by fluid shifts, especially edema, and its use
in longitudinal evaluations in this population have
been deferred. Studies have varied in their estimation
of dry weight BMI using either the postparacentesis
body weight or by subtracting a percentage of weight
based upon severity of ascites (mild, 5%; moderate,
10%; severe, 15%), with an additional 5% subtracted if
bilateral pedal edema was present.(4,34,35) More
advanced tools quantify specific body composition
compartments (such as adipose tissue depots [e.g., vis-
ceral adiposity] and/or skeletal muscle) with varying
accuracy and specificity (Table 3). These tools are
important in nutrition practices as they relate to poor
metabolic, clinical, and functional outcomes and will
be the focus of this section.(3,4,15,16)
Importantly, in addition to quantifying body com-
position compartments, CT imaging can be used to
evaluate the potential infiltration of fat into muscle by
examining changes in Hounsfield units, which crudely
reflect the density of muscle tissue. Similarly, the use
of echogenicity with ultrasonography may provide sim-
ilar measures of changes in muscle density, which may
reflect fatty infiltration or muscle damage. These mea-
sures may provide additional insight on possible rela-
tionships and mechanisms of poor muscle function
and health(36) but require validation before routine use
in clinical settings.
Special Considerations in Body Com-
position—Identifying Patients With
Low Muscle Mass
Cutoff points for low muscle mass in a cirrhosis
population have yet to be clearly defined or validated
using CT, MRI, or ultrasonography. This and stan-
dardized landmarks are needed to identify patients
with low muscle mass and compare results from differ-
ent studies (Table 4).
Special Considerations in Body
Composition—Understanding Sources
of Error
Understanding and controlling potential sources of
both modifiable errors (e.g., anatomical landmarking,
skill of tester) and nonmodifiable errors (i.e., base
assumptions incorporated into calculations) affect the
interpretation of results (Table 3). These errors are
particularly important in cirrhosis as patients frequently
present with fluid retention or shifts, ascites, or edema,
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factors that may confound single-point and longitudi-
nal assessments. For example, although a patient’s
weight may not change over time, muscle and adipose
tissue changes (i.e., fat and muscle loss) may be masked
by fluid retention or ascites. Although there are tools
(e.g., bioimpedance spectroscopy) to discriminate fluid
shifts from body composition changes, these devices
are not widely available due to cost. Further, repeated
CT or MRI scanning is limited by the expense, avail-
ability, and, in the case of CT, significant risk of ioniz-
ing radiation and contrast exposure to the patient.(37)
Preliminary data are available for thigh ultrasound as a
predictor of sarcopenia in cirrhosis, but this requires
the development of a universal approach as well as vali-
dation in cirrhosis and correlation with clinical
outcomes.(34)
#3 FUNCTIONAL ASSESSMENT
The quality of lean tissue, particularly skeletal muscle,
is optimally evaluated through functional measures. Sev-
eral studies have demonstrated that muscle strength
deteriorates more quickly than mass, suggesting that it
may be a more sensitive measure of “muscle health.”(38-
40) Moreover, in patients with cirrhosis, functional mea-
sures (e.g., handgrip, 6-minute walk, physical frailty,
TABLE 3. Characteristics of Diverse Body Composition Modalities That Have Been Used in Liver Cirrhosis
Modality Measures
Relative Accuracy
and Precision
Level of
Training Merits and Limitations
Anthropometrics Overall body size:
weight, height for
BMI; MAC
Predicted Muscle: MAMC
Predicted visceral adi-
posity: WC, W:H,
skinfold
Accuracy: Low
Precision: Low
Minimal Highly feasible, accessible, and inex-
pensive for large patient popula-
tions and clinics
Results need to be interpreted cau-
tiously as these are crude and
predictive
BIA Prediction equations to
calculate lean and fat
mass
Accuracy: Moderate
Precision: High
Minimal to
moderate
May present inaccuracies in patients
with ascites and/or edema
Feasible as a bedside tool and rela-
tively inexpensive to moderately
expensive
Proper positioning of inpatients or
patients who have a larger body
size may be challenging
Equations are used to predict whole-
body lean tissue based on same
device and population
Ultrasound
imaging
Muscle thickness and
CSA
Subcutaneous adipose
tissue
Echogenicity for tissue
integrity
Accuracy: Moderate
to high
Precision: Moderate
to high
Ultrasonographer
may be helpful
Moderately feasible and accessible in
clinics
Prediction equations for whole-body
lean or skeletal muscle mass are
needed
Cutoff points for low muscularity have
not been developed for cirrhosis
CT or MRI CSA and integrity of spe-
cific muscle and adi-
pose tissue groups
Accuracy: High
Precision: High
Certified medical
radiologist
Can capture specific lean and adi-
pose tissue deposits
Not performed on all patients
Only capture a single or few slice(s),
and prediction equations are
needed for whole-body lean mass
Specific cutoff points have not been
established in cirrhosis
Dual-energy X-ray
absorptiometry
Whole-body and regional
fat, lean, and bone
mineral content
Bone mineral density
Accuracy: High
Precision: High
Certified medical radiologist Low-dose radiation for prospective
studies
Can perform regional analysis
May not be available in clinic
Cannot specifically distinguish
between different tissue
compartments
Abbreviations: CSA, cross-sectional area; MAC, mid-arm circumference; MAMC, mid-arm muscle circumference; WC, waist cir-
cumference; W:H, weight to height ratio.
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and volume of O2 peak tests) have been associated with
clinical decompensation.(41-43) These measures are com-
plemented with body composition assessments to better
understand the metabolic integrity of the muscle and its
ability to perform its tasks.
#4 GLOBAL ASSESSMENT TOOLS
IN CIRRHOSIS
As a supplement to the performance of a detailed
nutritional assessment, we are aware of two global
assessment tools that incorporate some of the above
nutritional assessment parameters.
Subjective Global Assessment
The SGA(44) (Supporting Fig. S5) divides patients
into three categories based on five historical parameters
(weight change, dietary intake relative to usual, gastro-
intestinal symptoms, functional capacity, and metabol-
ic stress of underlying diagnosis) and three physical
examination parameters (loss of subcutaneous fat, loss
of muscle mass, and edema/ascites). The components
are combined to obtain a rating of A, well nourished;
B, moderately malnourished; or C, severely malnour-
ished. The SGA correlates well with adverse postoper-
ative outcomes in patients without cirrhosis(44) but
underestimates the prevalence of sarcopenia.(34) In a
recent study, of 69 patients identified to have sarcope-
nia by CT or MRI, only 46% were identified by the
SGA as being moderately or severely malnourished.
Moreover, in the setting of cirrhosis, unlike more
objective measures, the SGA has had a limited capacity
to predict clinical outcomes.(34,41)
Royal Free Hospital SGA
Recognizing the limitations of the traditional SGA
in the setting of cirrhosis, Morgan et al. devised the
Royal Free Hospital SGA, a global scheme incorporat-
ing both subjective and objective variables.(35) This
algorithm includes BMI (estimated dry body weight),
TABLE 4. Methods of Identifying Low Muscularity Using Various Body Composition Modalities and
Low Muscle Strength Using Hand Grip
Modality Calculations Required
Cutoff Point for Low
Muscularity/Strength
Population in
Which Cutoff Point
Was Derived
MAMC(13,14) MAMC (cm) 5 MAC (cm) –
(3.14 3 TSF [cm])
Females: <19.2 cm
Males: <21.1 cm
80 years old
BIA Skeletal muscle mass (kg) 5
[(Ht2 [m2]/R (Ohms) 3 0.401)
1 (sex [M 5 1, F 5 0] 3
3.825) 1 (age 3 –0.071)] 1
5.102(15)
Skeletal muscle index (kg/m2) 5
skeletal muscle mass
(kg)/height2 (m2)
Females: 5.76-6.75 kg/m2
associated with moderate physical
disability
5.75 kg/m2 associated with high
physical disability
Males:
8.51-10.75 kg/m2 associated with
moderate physical disability
8.50 kg/m2 associated with high
physical disability
Multiethnic
60 years old(16)
Ultrasound None None for the 4-site protocol Liver cirrhosis and ICU
CT or MRI Muscle index 5cross-sectional
area at L3 (cm2) / height2 (m2)
Females: <39 cm2/m2
Males: <54 cm2/m2
Cancer(17,18)
Dual-energy X-ray
absorptiometry
Appendicular lean mass index 5
sum of lean mass in upper and
lower limbs (kg)/height2 (m2)
Females: <5.45 kg/m2
Males: <7.26 kg/m2
Young and elderly(19)
Handgrip strength None Males:
BMI 24: 29 kg
BMI 24.1-28: 30 kg
BMI >28: 30 kg
Women:
BMI 23: 17 kg
BMI 23.1-26: 17.3 kg
BMI 26.1-29: 18 kg
BMI >29: 21 kg
65 years of age,
community-dwelling
participants in the
Cardiovascular
Health Study(20)
Abbreviations: ICU, intensive care unit; MAC, mid-arm circumference; MAMC, mid-arm muscle circumference; TSF, triceps
skinfold.
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mid-arm muscle circumference, and dietary intake
(Supporting Fig. S1). Notably, although nutritional
status as diagnosed by the Royal Free Hospital SGA
was significantly associated with a shorter survival in
men, it was not found to be prognostic in women, rais-
ing questions about its generalizability to both sexes.
The subjective interpretation required for scoring two
of the three variables, estimated dry body weight BMI
and dietary intake, may also raise some challenges.
Additional external validation is required before this
tool can be widely accepted.
Toward a Practical
Approach
 In cirrhosis, we suggest a minimum base-
line and longitudinal assessment of a 3-
day food diary, barriers to intake (question
3 of the patient-generated global SGA),
estimated dry weight BMI, and mid-arm
muscle circumference (Tables 4 and 5).
 Additional muscle health measures can be
used based on clinic capacity (budget,
training, etc.)
 Repetition of the base measures is essential
to inform clinical practice.
Special Considerations
IS THERE A DIFFERENCE IN
NUTRITIONAL ASSESSMENT
BETWEEN THE SEXES?
As a major objective component of malnutrition,
low muscularity or sarcopenia differs in men and wom-
en. This may result from the different prevalence of
autoimmune or cholestatic disease in women, but it is
likely that other factors also play a role. Usually women
have greater fat stores than men, while a progressive
depletion in muscle tissue is more evident in men.(45)
Moreover, the prognostic implications of low muscle
mass and function are less clear in female than in male
patients.(16) It has been suggested that hypogonadism
and testosterone deficiency in men with cirrhosis may
lead to chronic muscle depletion even before malnutri-
tion is clinically evident.(46)
INFLAMMATION
Recognizing the importance of inflammation in pro-
moting catabolism, Jensen and colleagues, as part of the
international clinical nutrition support community,(47)
proposed an etiology-based diagnosis of adult starvation
and disease-related malnutrition. They incorporated the
concept of inflammation, as an energy demanding con-
dition, to define three different categories of malnutri-
tion. Across the categories, energy needs progressively
increase and the response to nutritional therapy
decreases: (1) pure chronic starvation without inflam-
mation (e.g., anorexia nervosa), (2) chronic diseases or
conditions that impose sustained inflammation of a
mild to moderate degree (e.g., organ failure, pancreatic
cancer), and (3) acute disease or injury with a marked
inflammatory response (e.g., major infection, burns). At
present, the evidence suggests that patients with cirrho-
sis are conservatively designated as having mild to mod-
erate inflammation. Hospitalized patients with acute-
on-chronic liver failure are elevated to category 3.(48)
The use of specific inflammatory markers (i.e., C-
reactive protein or procalcitonin) to further refine the
categorization and predict the responsiveness to nutri-
tional supplementation requires evaluation.
OBESITY
The epidemic of obesity and the association between
nonalcoholic steatohepatitis and cryptogenic cirrhosis
have significantly increased the number of obese and
TABLE 5. Minimum Components of a Detailed Nutritional
Assessment For Patients With Cirrhosis
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morbidly obese patients with cirrhosis. As evidence,
nonalcoholic fatty liver disease is becoming a leading
indication for liver transplantation. Obese patients typ-
ically exhibit low inflammation, muscle and hepatic
insulin resistance, dyslipidemia, and/or other comor-
bidities. The combination of cirrhosis and obesity
exacerbates complications that may require specific
nutrition advice. Skeletal muscle atrophy may be
masked by adiposity when using BMI and BIA.
In ultrasound, distinguishing between the muscle
and subcutaneous adipose tissue border may also be
challenging in obese individuals, decreasing accura-
cy and reliability of ultrasound. While CT and
MRI may distinguish between muscle and adipose
tissue deposits, many obese individuals may not be
scanned due to the size restrictions of the scanner.
                                                                                                                                      
FIG. 3. A case example using the proposed algorithm for nutritional screening and assessment. Abbreviation: INR, international nor-
malized ratio.
                                                                                                                                      
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Generally, obesity increases the rate of clinical
decompensation in patients with cirrhosis,(49) and
morbid obesity (BMI >35) has been associated
with decreased survival after liver transplanta-
tion.(50) Given the limitations of existing bedside
tools in these patients and the practical issues asso-
ciated with repeated CT/MRI-based imaging, fur-
ther data are needed before recommendations can
be made about the ideal approach to nutritional
assessment in obese patients.
Towards a Practical Approach:
 The implications of female sex, inflamma-
tion, and obesity on the assessment of
nutritional status are complex and poorly
understood.
 All cirrhosis patients are considered to
have mild to moderate inflammation.
Conclusion
Malnutrition, regardless of definition, is an inde-
pendent predictor of poor clinical outcomes in cirrho-
sis. There is uncertainty in the areas of nutritional
screening and nutritional assessment in the popula-
tion of patients with cirrhosis. The approach to
patient management highlighted here is based on a
combination of the literature evidence, practice guide-
lines, and clinical experience. A case example using
the proposed approach is presented in Fig. 3.
Although common sense indicates that adoption of
even the minimal elements of nutrition screening and
assessment outweighs the issues associated with the
absence of validated tools and consensus in this area,
there is still much room for refinement. Future studies
need to assess the implications of sex, volume status,
inflammation, and obesity on nutritional screening
and assessment algorithms. The proposed approach
for nutritional screening and assessment requires pro-
spective validation and refinement, preferably in a
multicenter network. Practitioner and patient educa-
tion is also needed to increase awareness of and need
for surveillance of nutrition factors to prevent and/or
mitigate poor health outcomes, especially as these are
potentially modifiable. This approach will eventually
result in a practical, validated, and unified nutritional
screening/assessment strategy, which can be imple-
mented into routine clinical practice.
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